theory clinical_95_0
imports Main

begin

typedecl entity
typedecl event

consts
  Patient :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  Vemurafenib :: "entity ⇒ bool"
  Receive :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  With :: "entity ⇒ entity ⇒ bool"
  For :: "entity ⇒ entity ⇒ bool"
  V600EMutation :: "entity ⇒ bool"
  Recovery :: "entity ⇒ bool"
  Rapid :: "entity ⇒ bool"
  MAPKPathwaySignaling :: "entity ⇒ bool"
  Associated :: "event ⇒ bool"
  Resistance :: "entity ⇒ bool"
  BRAFInhibitors :: "entity ⇒ bool"
  Combination :: "entity ⇒ bool"
  MEKInhibitor :: "entity ⇒ bool"
  Yield :: "event ⇒ bool"
  Results :: "entity ⇒ bool"
  Better :: "entity ⇒ bool"
  Than :: "entity ⇒ entity ⇒ bool"
  VemurafenibMonotherapy :: "entity ⇒ bool"

(* Explanation 1: Patient could receive treatment with vemurafenib for V600E mutation. *)
axiomatization where
  explanation_1: "∃x y z e v. Patient x ∧ Treatment y ∧ Vemurafenib z ∧ Receive e ∧ Agent e x ∧ Agent e y ∧ With y z ∧ For y v ∧ V600EMutation v"

(* Explanation 2: Rapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors. *)
axiomatization where
  explanation_2: "∃x y e z. Recovery x ∧ Rapid x ∧ MAPKPathwaySignaling y ∧ Associated e ∧ Agent e x ∧ Resistance z ∧ BRAFInhibitors z ∧ With x z"

theorem hypothesis:
  assumes asm: "Combination x ∧ Vemurafenib y ∧ MEKInhibitor z"
  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)
  shows "∃x y z e w. Combination x ∧ Vemurafenib y ∧ MEKInhibitor z ∧ Yield e ∧ Agent e x ∧ Results w ∧ Better w ∧ Than w VemurafenibMonotherapy"
  sledgehammer
  oops

end
